Rheumatoid arthritis (RA) and migraine are both common disorders which are caused by a faulty immune system and autonomic nervous system dysfunction, respectively. Although current treatment outlook has been shown a great improvement in these two diseases, however many side effects have been reported.We report a case of 43-years-female that has been suffered from rheumatoid arthritis for 3 years with a 6 years history of migraine. She had used different types of medication for both rheumatoid arthritis and migraine but during these 6 years no improvement was observed and even migraine progression in this patient became worse. She was admitted to the hospital for 12 weeks follow up to evaluate the effect of β-D-mannuronic acid (M2000) on her RA disease. During 12 weeks of M2000 therapy RA indices including Disease Activity Score (DAS28), simple disease activity index(SDAI) and C-reactive protein (CRP),erythrocyte sedimentation rate (ESR), rheumatoid factor (RF)), anti-cyclic citrullinated peptide antibodies(anti-CCP) and blood determinants were measured.A significant improvement was seen after 12 weeks of M2000 therapy in both rheumatoid arthritis and migraine which are considered as inflammatory diseases. Therefore, it might be concluded that M2000 as a novel non-steroidal anti-inflammatory drugs (NSAIDs) with immunosuppressive property is able to treat migraine in addition to its potent efficacy on treatment of rheumatoid arthritis.

作者：Mahdi, Vojdanian；Hossein, Ahmadi；Ahmad Reza, Jamshidi；Mahdi, Mahmoudi；Farhad, Gharibdoost；Anis, Barati；Abbas, Mirshafiey

来源：Current clinical pharmacology 2017 年